Paragon Care Limited (AU:PGC)
ASX:PGC
Top Page
Paragon Care Limited
(Sydney:PGC)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.18
▼(-2.22% Downside)
Action:ReiteratedDate:03/26/26
The score is primarily held down by weak financial performance: steep revenue contraction, very thin margins, and negative operating/free cash flow. Technicals are mixed (near-term improvement vs. longer-term downtrend signals), while valuation is also a negative factor due to the negative P/E and lack of dividend yield data.
Positive Factors
Distribution + Services Model
The company’s combined distribution, installation and consumables model creates recurring service and consumables revenue and high customer switching costs with hospitals, labs and research customers, supporting stable through-cycle demand and long-term customer relationships.
Negative Factors
Steep revenue decline
A >20% revenue contraction reflects loss of sales or market share in core clinical and lab markets. Persistent top-line decline undermines operating leverage, constrains reinvestment capacity, and makes margin recovery and sustainable cash generation more difficult over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Distribution + Services Model
The company’s combined distribution, installation and consumables model creates recurring service and consumables revenue and high customer switching costs with hospitals, labs and research customers, supporting stable through-cycle demand and long-term customer relationships.
Read all positive factors
Paragon Care Limited (PGC) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$297.95M
Dividend YieldN/A
Average Volume (3M)501.29K
Price to Earnings (P/E)―
Beta (1Y)0.77
Revenue Growth21.68%
EPS Growth37.78%
CountryAU
Employees400
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)-1.29
Shares Outstanding1,655,305,400
10 Day Avg. Volume605,379
30 Day Avg. Volume501,285
Financial Highlights & Ratios
PEG Ratio0.78
Price to Book (P/B)1.90
Price to Sales (P/S)0.17
P/FCF Ratio-26.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.31Price Target Upside74.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$3.68B
Paragon Care Limited Business Overview & Revenue Model
Company Description
Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, inte...
How the Company Makes Money
null...
Paragon Care Limited Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
55
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.67B | 3.61B | 2.97B | 307.63M | 237.62M | 235.84M |
| Gross Profit | 243.16M | 324.00M | 176.07M | 51.68M | 36.58M | 33.41M |
| EBITDA | 41.04M | 89.81M | 43.18M | 37.07M | 23.96M | 26.54M |
| Net Income | -13.93M | 20.57M | 8.38M | 12.80M | 6.63M | 8.28M |
Balance Sheet | ||||||
| Total Assets | 1.31B | 1.23B | 1.13B | 448.52M | 438.44M | 291.92M |
| Cash, Cash Equivalents and Short-Term Investments | 30.86M | 21.90M | 19.94M | 970.00K | 46.20M | 33.20M |
| Total Debt | 464.29M | 296.52M | 251.83M | 122.14M | 131.26M | 113.01M |
| Total Liabilities | 1.00B | 915.04M | 838.97M | 196.56M | 196.31M | 170.40M |
| Stockholders Equity | 304.50M | 319.00M | 291.92M | 18.88M | 235.82M | 121.52M |
Cash Flow | ||||||
| Free Cash Flow | -13.40M | -23.04M | 25.14M | -3.30M | 14.42M | 22.18M |
| Operating Cash Flow | 2.61M | -11.35M | 44.45M | 17.75M | 19.03M | 27.46M |
| Investing Cash Flow | -46.98M | -16.64M | -19.52M | -31.75M | 7.07M | -18.80M |
| Financing Cash Flow | 58.05M | 28.65M | -5.95M | -10.00M | -11.93M | 32.00K |
Paragon Care Limited Technical Analysis
Negative
0.18
Price Trends
0.19
Negative
0.22
Negative
0.28
Negative
Market Momentum
>-0.01
Positive
40.50
Neutral
8.33
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:PGC, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.18, below the 50-day MA of 0.19, and below the 200-day MA of 0.28, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 40.50 is Neutral, neither overbought nor oversold. The STOCH value of 8.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:PGC.
Paragon Care Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | AU$30.89B | 22.26 | 12.63% | 0.44% | ― | ― | |
59 Neutral | AU$390.60M | 23.92 | 16.35% | 4.60% | 6.73% | 37.16% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$94.79M | -2.00 | -131.13% | ― | 456.50% | -457.14% | |
46 Neutral | AU$297.95M | -4.18 | -4.47% | ― | 21.68% | 37.78% | |
46 Neutral | AU$363.07M | -5.40 | -67.21% | ― | -23.02% | 33.11% | |
43 Neutral | AU$181.99M | -4.23 | -23.02% | ― | 5.07% | 46.14% |
* Healthcare Sector Average
AU:PGC
Paragon Care Limited
0.18
-0.22
-54.43%
AU:SIG
Sigma Healthcare Ltd
2.69
-0.27
-9.27%
AU:MYX
Mayne Pharma Group
2.24
-4.74
-67.91%
AU:HLS
Healius Limited
0.50
-0.52
-51.17%
AU:ACL
Australian Clinical Labs Ltd
2.07
-0.76
-26.75%
AU:BOT
Botanix Pharmaceuticals Limited
0.04
-0.32
-89.86%
Paragon Care Limited Corporate Events
Paragon Care Completes Acquisition of Haju Medical to Boost Asia Footprint
Apr 1, 2026
Paragon Care Limited has strengthened its regional footprint with the completion of its acquisition of PT Haju Medical Indonesia and Insightof Co., Ltd. through its Singapore subsidiary. The deal consolidates Paragon Care’s presence in the A...
Paragon Care outlines FY26 half-year update with strong disclaimers
Feb 25, 2026
Paragon Care Limited has released an investor presentation outlining its FY26 half-year results, providing shareholders with a high-level update on current activities and financial performance. The document emphasises that the material is informat...
Paragon Care Highlights Transformation in FY26 Half-Year Report
Feb 25, 2026
Paragon Care Limited has released its FY26 half-year report, highlighting its evolution into a leading diversified healthcare provider across the Asia-Pacific region. The company underscores its strategic transformation following the 2024 merger w...
Paragon Care formalises leadership transition as CEO Carmen Riley becomes Managing Director
Feb 24, 2026
Paragon Care has elevated Chief Executive Officer Carmen Riley to the dual role of CEO and Managing Director from 1 March 2026, formalising the next step in a succession plan first outlined in mid-2025. Riley, who has more than 15 years’ exp...
Paragon Care Sets Date for 1H FY26 Results and Investor Call
Feb 24, 2026
Paragon Care Limited, an Australian-listed healthcare provider, offers a broad range of medical equipment, devices, consumables, pharmaceuticals, complementary medicines, and nutritional supplies. The company also produces blood bank diagnostic re...
Paragon Care to Exit Low-Margin Ramsay Pharmacy Contract, Focus on Higher-Value Growth
Jan 16, 2026
Paragon Care will cease acting as the primary wholesaler to Ramsay Healthcare’s retail and hospital pharmacy operations from 1 February 2026 after its re-tender bid was undercut by a lower-priced competitor, a contract that added about A$230...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.